Search Tag: HFNO

ICU Management

2025 12 May

In ICUs, extubation decisions are challenging, as 20-30% of patients experience post-extubation respiratory failure, with 10-15% requiring reintubation. Reintubation has high mortality rates and is a key patient outcome in the post-extubation period.  Noninvasive ventilation (NIV) and high-flow nasal oxygen (HFNO) therapies, when applied imme1Read more

ICU Management

2022 19 Apr

High flow nasal oxygen (HFNO) has many physiological benefits in patients with acute hypoxaemic respiratory failure (AHRF). It can also help reduce the need for intubation. However, optimal flow settings are unknown and are generally based on expert recommendations.  Maintaining oxygenation within a given target range requires intensive patie1Read more

ICU Management

2022 23 Mar

Non-invasive ventilation (NIV) is recommended for immunocompromised patients with acute respiratory failure in the ICU. However, it can have harmful effects. High-flow nasal oxygen (HFNO) alone could be an alternative strategy to reduce mortality.  The HFNC Alone or Associated With NIV for Immunocompromised Patients Admitted to ICU for Acute R1Read more

ICU Management

2022 01 Feb

Non-invasive respiratory support is an essential part of critical care. Non-invasive ventilation and high-flow nasal oxygen (HFNO) are commonly used in patients with acute hypoxaemic respiratory failure.   Non-invasive respiratory support can alleviate respiratory distress, improve oxygenation and reduce the need for invasive mechanical ventilat1Read more

ICU Management

2021 07 Dec

Acute hypoxaemic respiratory failure (AHRF) is one of the most common causes of admission to the ICU. It has a mortality rate of nearly 30%. Non-invasive respiratory management strategies are recommended to avoid the risk of endotracheal intubation. However, patients with de novo acute hypoxaemic respiratory failure (AHRF) are often at high risk o1Read more

ICU Management

2021 14 Feb

COVID-19 has caused thousands of cases of acute respiratory failure with a high mortality rate. However, so far, the use of high-flow nasal oxygen (HFNO) has been limited even though it may be an appropriate initial therapy in COVID-19 patients with acute respiratory failure. The use of invasive mechanical ventilation remains the primary treatment1Read more